EVR:LSEEvraz PLC Analysis
Data as of 2026-05-22 - not real-time
$346.26
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Evercore delivered a record Q1 2026 with revenue climbing to $4.55 bn and a 16.4% profit margin, while operating margins held near 24% and ROE surged above 40%. EPS jumped to $17.76 and the forward estimate of $23.01 suggests continued earnings acceleration. The company’s dividend payout remains modest at 19% of earnings, supporting a sustainable 1.03% yield. Despite a price‑to‑earnings multiple of ~19.5x that exceeds the industry average of 16.7x, the DCF model flags a fair value near $1,014, implying the stock is still priced attractively relative to its cash generation and growth prospects. Technically, the share price of $346 sits above the 20‑day, 50‑day and 200‑day SMAs, indicating short‑term bullish momentum, though the MACD histogram has turned negative and volume is trending down, tempering the upside.
Risk factors include a 30‑day volatility of roughly 33% and a beta above 1.8, pointing to heightened market sensitivity. The decreasing trading volume and a sizable max drawdown of ~30% suggest liquidity and downside risk, while the capital‑markets sector carries moderate regulatory exposure. Overall, the fundamentals are strong, the dividend is sustainable, but valuation appears only marginally justified, leading to a cautious yet positive outlook.
Risk factors include a 30‑day volatility of roughly 33% and a beta above 1.8, pointing to heightened market sensitivity. The decreasing trading volume and a sizable max drawdown of ~30% suggest liquidity and downside risk, while the capital‑markets sector carries moderate regulatory exposure. Overall, the fundamentals are strong, the dividend is sustainable, but valuation appears only marginally justified, leading to a cautious yet positive outlook.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Q1 earnings beat expectations
- Price above key moving averages
- Support level near $311.6 providing downside cushion
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- PE multiple above industry peers
- Negative MACD histogram indicating potential pullback
- Sustained dividend with low payout ratio
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- High ROE and strong cash flow generation
- DCF fair value suggests significant upside
- Diversified global footprint reduces geographic concentration
Key Metrics & Analysis
Financial Health
Revenue Growth100.30%
Profit Margin16.40%
P/E Ratio19.5
ROE42.17%
ROA21.35%
Debt/Equity52.59
P/B Ratio7.5
Op. Cash Flow$1.6B
Industry P/E16.7
Technical Analysis
TrendNeutral
RSI57.9
Support$311.60
Resistance$351.65
MA 20$333.62
MA 50$319.79
MA 200$326.57
MACDBearish
VolumeDecreasing
Fear & Greed Index90.93
Valuation
Fair Value$1,014.23
Target Price$374.60
Upside/Downside8.18%
GradeFair
TypeBlend
Dividend Yield1.03%
Risk Assessment
Beta1.84
Volatility32.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.